Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Contineum Therapeutics Inc (CTNM)

Contineum Therapeutics Inc (CTNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 476,407
  • Shares Outstanding, K 37,336
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,980 K
  • EBIT $ -68 M
  • EBITDA $ -68 M
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.84

Options Overview Details

View History
  • Implied Volatility 162.76% (+4.97%)
  • Historical Volatility 72.61%
  • IV Percentile 14%
  • IV Rank 13.09%
  • IV High 502.36% on 06/02/25
  • IV Low 111.58% on 01/23/26
  • Expected Move (DTE 2) 0.00 (0.00%)
  • Put/Call Vol Ratio 9.00
  • Today's Volume 10
  • Volume Avg (30-Day) 25
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 242
  • Open Int (30-Day) 225
  • Expected Range 12.97 to 12.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.55
  • Number of Estimates 4
  • High Estimate $-0.49
  • Low Estimate $-0.61
  • Prior Year $-0.62
  • Growth Rate Est. (year over year) +11.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.80 +9.92%
on 03/19/26
14.20 -8.66%
on 03/27/26
-0.03 (-0.23%)
since 03/13/26
3-Month
10.84 +19.65%
on 01/15/26
16.33 -20.58%
on 02/24/26
+1.21 (+10.29%)
since 01/14/26
52-Week
3.35 +287.16%
on 05/29/25
16.33 -20.58%
on 02/24/26
+8.98 (+225.06%)
since 04/14/25

Most Recent Stories

More News
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 12.97 (+1.65%)
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

- Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data...

CTNM : 12.97 (+1.65%)
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 12.97 (+1.65%)
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 12.97 (+1.65%)
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 12.97 (+1.65%)
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 12.97 (+1.65%)
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

Contineum Therapeutics, Inc. (Nasdaq: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 12.97 (+1.65%)
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and...

CTNM : 12.97 (+1.65%)
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

- PIPE-307 demonstrated an acceptable safety and tolerability profile - PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast...

CTNM : 12.97 (+1.65%)
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

- Topline data from the PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS) is anticipated in the fourth quarter of 2025 ...

CTNM : 12.97 (+1.65%)

Business Summary

Contineum Therapeutics Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies which target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications...

See More

Key Turning Points

3rd Resistance Point 13.86
2nd Resistance Point 13.62
1st Resistance Point 13.29
Last Price 12.97
1st Support Level 12.72
2nd Support Level 12.48
3rd Support Level 12.15

See More

52-Week High 16.33
Last Price 12.97
Fibonacci 61.8% 11.37
Fibonacci 50% 9.84
Fibonacci 38.2% 8.31
52-Week Low 3.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.